Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on August 22, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

NOTICE OF INTENT FOR MOUSE ANTIBODY PRODUCTION SERVICE PHASES I-IV

Closed
NOI-NIAID-24-2230329Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

NAICS

541380 - Testing Laboratories and Services

Place of Performance

Bethesda, MD, 20814, USA

Set-Aside

NONE

Documents

1

NOI-NIAID-24-2230329 Mouse Antibody Production Service Phases I-IV

PDF, Low prioritypresolicitation
Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts1 person available
OfficeBETHESDA, MD, 20892, USA
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more
PRE-SOLICITATION NOTICE Title: Mouse antibody production service phases I-IV ID: NOI-NIAID-24-2230329 Post Date: August 22, 2024 Response Date: September 3, 2024 NAICS: 541380 Introduction This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Creative Biolabs, Inc. of Shirley, New York to procure Antibody development and library construction and screening services. The Laboratory of Immunoregulation (LIR) is requesting the following service: Mice will be immunized by a vector expressing our antigen of interest. Creative Biolabs will generate a phage display mouse antibody library and screen the resulting library to find the target specific antibodies. Once they identify the specific antibodies sequences, they can further produce purified monoclonal antibodies. Description of need: Phase I - Mice immunization, RNA extraction & quality test, cDNA production, PCR amplification of the antibody, repertoires, ligation and transformation, library validation,QTY 1 ea Phase II: scFV library screening, Binder Phage validation, sequence delivery, QTY 1 Phase III: Antibody Expression and Purification, Blocking Activity Test by FACS, QTY 1 set Phase IV: Affinity measurement, Phage scFV construct, Mutant scVF, Biopanning, Phage Elisa, Mutant IgG production, Affinity measure, Milestone 2 (At least one IgG - 100 fold, QTY 1 set Shipping and handling The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered. If your organization has the potential capacity to support this requirement, please provide the following information: 1) organization name, address, point of contact, email address, website address, telephone number, UEI number and size and type of ownership for the organization; and 2) respondents shall indicate if they provide these laboratory services. This shall include basic information on product specifications. If an equal product is recommended (not specific to the brand proposed) then sufficient details shall be provided by the respondent describing how the equal product being recommended, meets the minimum specifications of the requirement. Submission Instructions Interested businesses who consider themselves qualified to provide the above-listed items are invited to submit a response to this Notice of Intent by September 3, 2024 at 10:00 AM EST. All responses under this Notice of Intent must be submitted via the NIAID electronic Simplified Acquisition Submission System (eSASS) website at https://esass.nih.gov. All vendors must register in the eSASS system to submit their documentation. Instructions on how to register /submit documents are included on the website. All responses received by the closing date of this synopsis will be considered by the Government. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 811210
New
Federal
1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC)
Solicitation # NOI-NIAID-27-2279300
The National Institutes of Health NIAID intends to award a firm-fixed price sole source contract to Revvity Health Sciences, Inc. for a one-year maintenance and service agreement for two Revvity Celigo S imaging instruments. The period of performance is scheduled from November 15, 2026, through November 14, 2027. This procurement is categorized under NAICS code 811210 for electronic and precision equipment repair and maintenance. The government is utilizing statutory authority 41 U.S.C. 3304(a)(1) and FAR 6.302.1(b)(1)(i), asserting that Revvity Health Sciences is the only responsible source capable of satisfying the requirement due to their proprietary access to diagnostic tools, service documentation, and genuine replacement parts. The scope of work includes priority response for unlimited repair travel, labor, and parts, as well as remote support and minor hardware and software updates to ensure the instruments meet manufacturer specifications. While the government intends to negotiate directly with the OEM, interested qualified sources were invited to submit capability statements by November 4, 2026, to the contracting officer, Linda Smith, and acquisition specialist, Jessica Emerson. The final award is expected to be issued within five days of the notice closing.
Electronic and Precision Equipment Repair and Maintenance

POSTED

3 days ago

DEADLINE

in 6 days
View Details
NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

20 days ago

DEADLINE

in about 1 month
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS